MetrioPharm Investor-Update QI 2025
Notice of Extraordinary General Meeting of MetrioPharm AG
Dear shareholders,
An Extraordinary General Meeting of MetrioPharm AG will be held in Zurich on Thursday, April 17th, 2025 at 10:00 a.m. All shareholders registered in the share registry have already been informed by regular mail. Non-registered shareholders can contact MetrioPharm directly at: invest@metriopharm.com
The 19th Annual General Meeting of MetrioPharm AG is scheduled for June 16th.
MetrioPharm AG Company Calendar 2025
11-12 January: Longwood Healthcare Leaders Conference at JPMorgan Healthcare Conference, San Francisco, USA
13-15 January: Biotech Showcase at JP Morgan Healthcare Conference, San Francisco, USA
14 January: Annual Wuxi Global Forum 2025 at JP Morgan Healthcare Conference, San Francisco, USA
14-17 January: PPMD Duchenne Healthcare Provider Summit, San Diego, USA
31 January: Swiss Biotech CEO Meeting, Bern, Switzerland
26-27 February: Sachs Annual European Life Sciences CEO Forum, Zurich, Switzerland
16-19 March: Muscular Dystrophy Association Clinical & Scientific Conference, Dallas, USA
17-19 March: Bio-Europe Spring, Milan, Italy
28-29 March: Duchenne UK New Horizons Conference, London, UK
05-06 May: Swiss Biotech Day 2025, Basel, Switzerland
16-19 June: BIO International Convention, Boston, USA
19-21 June: Parent Project Muscular Dystrophy (PPMD) Annual Conference, Las Vegas, USA
MetrioPharm AG informs
MetrioPharm uses various channels to inform its shareholders:
Alongside the quarterly newsletter, we also keep you up to date on current developments in the company with press releases.
If you have not yet been included in our press mailing list, please send us an e-mail to invest@metriopharm.com.
Please feel free to network with us via LinkedIn.
We use our LinkedIn profile to inform shareholders, experts and business partners about the latest company developments.
Your contact:
MetrioPharm
Investor Relations
T + 41 44 552 7190
E invest@metriopharm.com
W www.metriopharm.com